Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48


Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Keck ZY, Saha A, Xia J, Wang Y, Lau P, Krey T, Rey FA, Foung SK.

J Virol. 2011 Oct;85(20):10451-63. doi: 10.1128/JVI.05259-11. Epub 2011 Aug 3.


The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.

Pawlotsky JM.

Gastroenterology. 2011 Mar;140(3):746-54. doi: 10.1053/j.gastro.2011.01.028. Epub 2011 Jan 18. No abstract available. Erratum in: Gastroenterology. 2011 Aug;141(2):778.


Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.

Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, McKeating JA, Witteveldt J, Patel AH, Alter H, Rice CM, Foung SK.

J Virol. 2009 Jun;83(12):6149-60. doi: 10.1128/JVI.00248-09. Epub 2009 Mar 25.


Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen.

Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC.

Nat Protoc. 2009;4(3):372-84. doi: 10.1038/nprot.2009.3. Erratum in: Nat Protoc. 2014 Nov 20;9(12):2903.


Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.

Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J.

Hepatology. 2009 Feb;49(2):364-77. doi: 10.1002/hep.22673.


Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection.

Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, Rosen CB, Heimbach JK, Charlton MR.

Am J Transplant. 2008 Nov;8(11):2426-33. doi: 10.1111/j.1600-6143.2008.02362.x. Epub 2008 Aug 22.


Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies.

Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, Patel AH, Ball JK, Lemon SM, Foung SK.

J Virol. 2008 Jun;82(12):6061-6. doi: 10.1128/JVI.02475-07. Epub 2008 Apr 9.


A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope.

Keck ZY, Olson O, Gal-Tanamy M, Xia J, Patel AH, Dreux M, Cosset FL, Lemon SM, Foung SK.

J Virol. 2008 Jun;82(12):6067-72. doi: 10.1128/JVI.00252-08. Epub 2008 Apr 2.


Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.

Owsianka AM, Tarr AW, Keck ZY, Li TK, Witteveldt J, Adair R, Foung SK, Ball JK, Patel AH.

J Gen Virol. 2008 Mar;89(Pt 3):653-9. doi: 10.1099/vir.0.83386-0.


Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.

Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR.

Nat Med. 2008 Jan;14(1):25-7. Epub 2007 Dec 6.


Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.

Perotti M, Mancini N, Diotti RA, Tarr AW, Ball JK, Owsianka A, Adair R, Patel AH, Clementi M, Burioni R.

J Virol. 2008 Jan;82(2):1047-52. Epub 2007 Nov 7.


Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.

Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuisson J, Persson MA.

Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16269-74. Epub 2007 Oct 2.


Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins.

Delgrange D, Pillez A, Castelain S, Cocquerel L, Rouillé Y, Dubuisson J, Wakita T, Duverlie G, Wychowski C.

J Gen Virol. 2007 Sep;88(Pt 9):2495-503.


Isolating and engineering human antibodies using yeast surface display.

Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD.

Nat Protoc. 2006;1(2):755-68.


Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.

von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, McKeating JA.

Gastroenterology. 2007 Feb;132(2):667-78. Epub 2006 Dec 3.


Hepatitis C virus and liver transplantation.

Verna EC, Brown RS Jr.

Clin Liver Dis. 2006 Nov;10(4):919-40. Review.


Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.

Keck ZY, Xia J, Cai Z, Li TK, Owsianka AM, Patel AH, Luo G, Foung SK.

J Virol. 2007 Jan;81(2):1043-7. Epub 2006 Nov 1.


Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding.

Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH, Ball JK.

J Virol. 2006 Sep;80(17):8695-704.


Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells.

Cai Z, Zhang C, Chang KS, Jiang J, Ahn BC, Wakita T, Liang TJ, Luo G.

J Virol. 2005 Nov;79(22):13963-73.

Supplemental Content

Support Center